专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009055823A3 METHOD TO PREDICT RESPONSIVENESS OF BREAST CANCER TO POLYAMINETYPE CHEMOTHERAPY 审中-公开
标题翻译：预防乳腺癌对聚氨酯治疗的反应方法
公开(公告)号：WO2009055823A3
公开(公告)日：2010-01-07
申请号：PCT/US2008081385
申请日：2008-10-27
申请人： PROGEN PHARMACEUTICALS LTD , UNIV CALIFORNIA , GRAY JOE W , MARTON LAURENCE , DAS DEBOPRYIA , KUO WEN-LIN , WANG NICHOLAS , NEVE RICHARD , SPELLMAN PAUL , FRIDLYAND JANE , CHIN KOEI , HU ZHI
发明人： GRAY JOE W , MARTON LAURENCE , DAS DEBOPRYIA , KUO WEN-LIN , WANG NICHOLAS , NEVE RICHARD , SPELLMAN PAUL , FRIDLYAND JANE , CHIN KOEI , HU ZHI
IPC分类号： G01N33/48 , A61K31/04
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178
摘要： The invention provides for a method for identifying a cancer patient, such as a breast cancer patient, suitable for treatment with a conformationally-restricted polyamine, such as CGC-11047, comprising detecting modulated expression of one or more of a set of predictive biomarker genes or proteins in response to treatment with the conformationally-restricted polyamine. The invention further provides for a method of identifying a basal or luminal phenotype of a cell, comprising detecting expression of one or more of a set of predictive biomarker genes or proteins that identify the cell as having a basal or luminal cancer subtype.
摘要翻译：本发明提供了一种用于鉴定适合用构象限制性多胺（例如CGC-11047）治疗的癌症患者例如乳腺癌患者的方法，其包括检测一组或多种预测性生物标记基因的调节表达或蛋白质，以响应用构象限制的多胺处理。本发明进一步提供了鉴定细胞的基底或腔表型的方法，其包括检测一组预测性生物标志物基因或蛋白质中的一种或多种的表达，所述基因或蛋白质鉴定为具有基底或腔内癌症亚型的细胞。

2. 发明申请

WO2007143752A3 TARGETS IN BREAST CANCER FOR PROGNOSIS OR THERAPY 审中-公开
标题翻译：乳腺癌中的目标用于预防或治疗
公开(公告)号：WO2007143752A3
公开(公告)日：2008-09-25
申请号：PCT/US2007070908
申请日：2007-06-11
申请人： UNIV CALIFORNIA , GRAY JOE W , FRIDLYAND JANE , NEVE RICHARD , SPELLMAN PAUL , CHIN KOEI , HU ZHI , WALDMAN FREDERIC
发明人： GRAY JOE W , FRIDLYAND JANE , NEVE RICHARD , SPELLMAN PAUL , CHIN KOEI , HU ZHI , WALDMAN FREDERIC
IPC分类号： C12P19/34 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136
摘要： Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8pl 1, 1 Iql3, 17ql2, and 20ql3 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers.
摘要翻译：癌症标志物被开发用于检测特征在于凋亡抑制基因如侵袭性癌症的表达增加的疾病。基因组分析的乳腺癌基因组拷贝数和基因表达显示人类染色体区域中的66个基因，扩增出8pl1,1Iql3,17q2和20ql3。显示为扩增的基因的扩增水平的诊断和评估可用于预测患者在乳腺癌中的反应和耐药性的结果。通过鉴定涉及基因组序列的复发性畸变，拷贝数和/或基因表达与某些疾病和癌症特别是乳腺癌中的存活时间减少有关，某些基因被认为是高度优先的治疗靶点。这些基因的抑制剂将是治疗这些非反应性癌症的有用治疗方法。

3. 发明申请

WO2006081158A3 PREDICTIVE AND THERAPEUTIC MARKERS IN OVERIAN CANCER 审中-公开
标题翻译：预防和治疗标记在OVERANAN CANCER
公开(公告)号：WO2006081158A3
公开(公告)日：2007-02-01
申请号：PCT/US2006002202
申请日：2006-01-19
申请人： UNIV CALIFORNIA , GRAY JOE W , GUAN YINGHUI , KUO WEN-LIN , FRIDLYAND JANE , MILLS GORDON B
发明人： GRAY JOE W , GUAN YINGHUI , KUO WEN-LIN , FRIDLYAND JANE , MILLS GORDON B
IPC分类号： C12Q1/00 , A01N61/00 , C07H21/02 , C12Q1/68 , G01N33/53
CPC分类号： G01N33/57449 , G01N2800/44 , G01N2800/52
摘要： Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, Ilql3, 20qll-ql3, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVTl, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVTl, target drug resistance in ovarian cancer patients with low survival rates is described.
摘要翻译：可以开发癌症标记物以检测特征在于凋亡抑制基因如侵袭性癌症的表达增加的疾病。发现人染色体区域中的基因8q24，Ilql3,20qll-ql3被扩增，表明在诸如卵巢癌之类的疾病中的体内耐药性。扩增级别的诊断和评估显示扩增的某些基因，包括PVT1，可用于预测低存活率的卵巢癌患者患者反应和耐药性差的结果。通过鉴定涉及基因组序列的复发性畸变，拷贝数和/或基因表达与某些疾病和癌症（特别是卵巢癌）的生存期降低有关，某些基因被认为是高度优先的治疗靶点。描述了抑制这些基因之一的抑制剂的治疗剂，PVT1，具有低存活率的卵巢癌患者中的靶药耐药性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式